CN104869992A - 具有电压门控性钠通道选择性活性的n-取代的吲唑磺酰胺化合物 - Google Patents
具有电压门控性钠通道选择性活性的n-取代的吲唑磺酰胺化合物 Download PDFInfo
- Publication number
- CN104869992A CN104869992A CN201380068064.9A CN201380068064A CN104869992A CN 104869992 A CN104869992 A CN 104869992A CN 201380068064 A CN201380068064 A CN 201380068064A CN 104869992 A CN104869992 A CN 104869992A
- Authority
- CN
- China
- Prior art keywords
- base
- indazole
- sulfonamide
- alkyl
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C*CCC1)C2=C1C=CCC2 Chemical compound CC(C*CCC1)C2=C1C=CCC2 0.000 description 4
- LBUJPTNKIBCYBY-UHFFFAOYSA-N C1CNc2ccccc2C1 Chemical compound C1CNc2ccccc2C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 1
- ZNNFNEIFQIAWNY-UHFFFAOYSA-N Fc(cc1[nH]ncc1c1)c1Br Chemical compound Fc(cc1[nH]ncc1c1)c1Br ZNNFNEIFQIAWNY-UHFFFAOYSA-N 0.000 description 1
- HVQNLMVZPJQGFB-UHFFFAOYSA-N Fc1cc([nH]nc2)c2cc1SCc1ccccc1 Chemical compound Fc1cc([nH]nc2)c2cc1SCc1ccccc1 HVQNLMVZPJQGFB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261719118P | 2012-10-26 | 2012-10-26 | |
| US61/719,118 | 2012-10-26 | ||
| PCT/US2013/066360 WO2014066491A1 (en) | 2012-10-26 | 2013-10-23 | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104869992A true CN104869992A (zh) | 2015-08-26 |
Family
ID=50545213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380068064.9A Pending CN104869992A (zh) | 2012-10-26 | 2013-10-23 | 具有电压门控性钠通道选择性活性的n-取代的吲唑磺酰胺化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9388179B2 (enExample) |
| EP (1) | EP2911663B1 (enExample) |
| JP (1) | JP2015535252A (enExample) |
| KR (1) | KR20150074123A (enExample) |
| CN (1) | CN104869992A (enExample) |
| AU (1) | AU2013334664A1 (enExample) |
| BR (1) | BR112015008987A2 (enExample) |
| CA (1) | CA2891056A1 (enExample) |
| RU (1) | RU2015119640A (enExample) |
| WO (1) | WO2014066491A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020192553A1 (zh) * | 2019-03-22 | 2020-10-01 | 上海海雁医药科技有限公司 | 磺酰基取代的苯并杂环甲酰胺衍生物、其制法与医药上的用途 |
| WO2023186058A1 (zh) * | 2022-03-31 | 2023-10-05 | 江苏恒瑞医药股份有限公司 | 吲唑类化合物、其制备方法及其在医药上的应用 |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8933236B2 (en) | 2012-05-22 | 2015-01-13 | Xenon Pharmaceuticals Inc. | N-substituted benzamides and methods of use thereof |
| WO2013064984A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
| JP6014154B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用 |
| BR112015000187A2 (pt) | 2012-07-06 | 2017-06-27 | Genentech Inc | benzamidas substituídas com n e métodos de uso das mesmas |
| KR20150131233A (ko) | 2013-03-14 | 2015-11-24 | 제넨테크, 인크. | 치환된 트리아졸로피리딘 및 이의 사용 방법 |
| US9493429B2 (en) | 2013-03-15 | 2016-11-15 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
| CR20160296A (es) | 2013-11-27 | 2016-09-20 | Genentech Inc | Benzamidas sustituidas y métodos para usarlas |
| WO2016007534A1 (en) | 2014-07-07 | 2016-01-14 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| US9783527B2 (en) * | 2014-09-16 | 2017-10-10 | Abbvie Inc. | Indazole ureas and method of use |
| WO2016149169A1 (en) * | 2015-03-13 | 2016-09-22 | Abbvie Inc. | (indazol-4-yl)hexahydropyrrolopyrrolones and method of use |
| EP3297989A1 (en) | 2015-05-22 | 2018-03-28 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| CN108137477A (zh) | 2015-08-27 | 2018-06-08 | 基因泰克公司 | 治疗化合物及其使用方法 |
| CN108290881B (zh) | 2015-09-28 | 2021-12-07 | 健泰科生物技术公司 | 治疗性化合物和其使用方法 |
| EP3380466A1 (en) | 2015-11-25 | 2018-10-03 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
| SG11201804936UA (en) | 2015-12-18 | 2018-07-30 | Merck Sharp & Dohme | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| US10766858B2 (en) | 2016-03-30 | 2020-09-08 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| CN109526219B (zh) | 2016-05-20 | 2021-03-12 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
| MX388175B (es) | 2016-10-17 | 2025-03-19 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| SG10201912372XA (en) | 2016-12-09 | 2020-02-27 | Xenon Pharmaceuticals Inc | Benzenesulfonamide compounds and their use as therapeutic agents |
| EP3601273B1 (en) | 2017-03-24 | 2021-12-01 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
| CN107247885B (zh) * | 2017-07-06 | 2020-07-03 | 中国水产科学研究院黄海水产研究所 | 一种电压-门控钠离子通道的结构预测方法 |
| CN112041313A (zh) | 2018-02-26 | 2020-12-04 | 基因泰克公司 | 吡啶-磺酰胺化合物及其针对疼痛和相关疾患的用途 |
| JP2021519788A (ja) | 2018-03-30 | 2021-08-12 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ナトリウムチャネル阻害剤としての縮合環ヒドロピリド化合物 |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| UA127024C2 (uk) | 2018-06-13 | 2023-03-15 | Ксенон Фармасьютікалз Інк. | Бензолсульфонамідні сполуки та їх застосування як терапевтичних агентів |
| PE20211066A1 (es) | 2018-08-31 | 2021-06-09 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos |
| WO2020047312A1 (en) | 2018-08-31 | 2020-03-05 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
| US12227484B2 (en) | 2022-02-14 | 2025-02-18 | Arase Therapeutics Inc. | Inhibitors of PARG |
| WO2024173234A1 (en) * | 2023-02-13 | 2024-08-22 | Arase Therapeutics Inc. | Inhibitors of parg |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101218235A (zh) * | 2005-05-10 | 2008-07-09 | 沃泰克斯药物股份有限公司 | 作为离子通道调控剂的二环衍生物 |
| US20090023740A1 (en) * | 2007-07-13 | 2009-01-22 | Icagen | Sodium channel inhibitors |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3705185A (en) | 1969-04-14 | 1972-12-05 | Minnesota Mining & Mfg | N-aroyl sulfonamides |
| US4242273A (en) | 1977-09-27 | 1980-12-30 | American Cyanamid Company | 4-(Monoalkylamino)benzoic acid amides and imidates |
| US4136256A (en) | 1977-09-27 | 1979-01-23 | American Cyanamid Company | 4-(monoalkylamino)benzoic acid imidates |
| US4309553A (en) | 1977-09-27 | 1982-01-05 | American Cyanamid Company | Aldehydes and ketones containing a 4-(monoalkylamino)-benzoyl substituent |
| US4254138A (en) | 1977-12-19 | 1981-03-03 | American Cyanamid Company | Esters of 4-(monoalkylamino)benzoic hydroxyalkanoic acids |
| US4272546A (en) | 1977-12-19 | 1981-06-09 | American Cyanamid Company | Esters of 4-(monoalkylamino)benzoic hydroxyalkanoic acids |
| US4243609A (en) | 1978-02-02 | 1981-01-06 | American Cyanamid Company | Ring-fluorinated 4-(hexadecyl-amino) N-substituted benzamide compounds |
| US4211783A (en) | 1978-03-20 | 1980-07-08 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic novel 4-(aralkyl- and heteroarylalkylamino)phenyl compounds |
| US4230878A (en) | 1978-03-08 | 1980-10-28 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic 4-[(cyclopropyl alkyl)amino]benzoic acids and derivatives |
| US4227014A (en) | 1978-02-27 | 1980-10-07 | American Cyanamid Company | 4-[(Cycloalkyl or cycloalkenyl substituted)amino, alkylamino or alkenylamino]benzoic acids and salts thereof |
| US4230628A (en) | 1978-04-12 | 1980-10-28 | American Cyanamid Company | 4-[(Carboxyl- and sulfamyl-substituted alkyl)-amino] benzoic acids and analogs |
| US4245097A (en) | 1978-02-27 | 1981-01-13 | American Cyanamid Company | 4-[(Monosubstituted-alkyl) amino] benzoic acids and analogs as hypolipidemic and antiatherosclerotic agents |
| US4205085A (en) | 1978-03-09 | 1980-05-27 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino)phenyl compounds |
| US4305959A (en) | 1978-03-09 | 1981-12-15 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds |
| US4310545A (en) | 1978-03-09 | 1982-01-12 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino) phenyl compounds |
| US4318914A (en) | 1978-03-09 | 1982-03-09 | American Cyanamid Company | Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds |
| US4485105A (en) | 1978-10-12 | 1984-11-27 | American Cyanamid Company | Method of treating hyperlipidemia with 4-(monoalkylamino)benzoic acid amides |
| DK471479A (da) | 1978-12-13 | 1980-06-14 | Pfizer | Fremgangsmaade til fremstilling af imidazolderivater og salte deraf |
| US4670421A (en) | 1982-07-12 | 1987-06-02 | American Cyanamid Company | Antiatherosclerotic silanes |
| JP4316787B2 (ja) | 2000-01-11 | 2009-08-19 | 壽製薬株式会社 | エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、 |
| SE0402762D0 (sv) * | 2004-11-11 | 2004-11-11 | Astrazeneca Ab | Indazole sulphonamide derivatives |
| AU2009307892A1 (en) * | 2008-10-23 | 2010-04-29 | Merck Sharp & Dohme Corp. | Fused heterocyclic M1 receptor positive allosteric modulators |
| CN102348697B (zh) | 2009-01-12 | 2014-12-10 | 辉瑞股份有限公司 | 磺酰胺衍生物 |
| JP5830534B2 (ja) | 2010-07-09 | 2015-12-09 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化合物 |
| ES2532356T3 (es) | 2010-07-09 | 2015-03-26 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje |
| JP5860045B2 (ja) | 2010-07-09 | 2016-02-16 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化合物 |
| CA2800971A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| US8772343B2 (en) | 2010-07-12 | 2014-07-08 | Pfizer Limited | Chemical compounds |
| US9096500B2 (en) | 2010-07-12 | 2015-08-04 | Pfizer Limited | Acyl sulfonamide compounds |
| ES2532357T3 (es) | 2010-07-12 | 2015-03-26 | Pfizer Limited | Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor |
| US9514344B2 (en) | 2010-11-10 | 2016-12-06 | Datalogic ADC, Inc. | Adaptive data reader and method of operating |
| WO2012095781A1 (en) * | 2011-01-13 | 2012-07-19 | Pfizer Limited | Indazole derivatives as sodium channel inhibitors |
| CA2844799A1 (en) | 2011-08-17 | 2013-02-21 | Amgen Inc. | Heteroaryl sodium channel inhibitors |
| WO2013064984A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
| JP6014154B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用 |
| WO2013086229A1 (en) | 2011-12-07 | 2013-06-13 | Amgen Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| WO2013134518A1 (en) | 2012-03-09 | 2013-09-12 | Amgen Inc. | Sulfamide sodium channel inhibitors |
-
2013
- 2013-10-23 BR BR112015008987A patent/BR112015008987A2/pt not_active IP Right Cessation
- 2013-10-23 AU AU2013334664A patent/AU2013334664A1/en not_active Abandoned
- 2013-10-23 RU RU2015119640A patent/RU2015119640A/ru not_active Application Discontinuation
- 2013-10-23 US US14/437,142 patent/US9388179B2/en active Active
- 2013-10-23 JP JP2015539755A patent/JP2015535252A/ja active Pending
- 2013-10-23 EP EP13849733.4A patent/EP2911663B1/en active Active
- 2013-10-23 CA CA2891056A patent/CA2891056A1/en not_active Abandoned
- 2013-10-23 WO PCT/US2013/066360 patent/WO2014066491A1/en not_active Ceased
- 2013-10-23 KR KR1020157013297A patent/KR20150074123A/ko not_active Withdrawn
- 2013-10-23 CN CN201380068064.9A patent/CN104869992A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101218235A (zh) * | 2005-05-10 | 2008-07-09 | 沃泰克斯药物股份有限公司 | 作为离子通道调控剂的二环衍生物 |
| US20090023740A1 (en) * | 2007-07-13 | 2009-01-22 | Icagen | Sodium channel inhibitors |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020192553A1 (zh) * | 2019-03-22 | 2020-10-01 | 上海海雁医药科技有限公司 | 磺酰基取代的苯并杂环甲酰胺衍生物、其制法与医药上的用途 |
| WO2020192588A1 (zh) * | 2019-03-22 | 2020-10-01 | 上海海雁医药科技有限公司 | 烷基氨磺酰基吲唑羧酰胺衍生物、其制法与医药上的用途 |
| WO2023186058A1 (zh) * | 2022-03-31 | 2023-10-05 | 江苏恒瑞医药股份有限公司 | 吲唑类化合物、其制备方法及其在医药上的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015008987A2 (pt) | 2017-07-04 |
| AU2013334664A1 (en) | 2015-05-07 |
| KR20150074123A (ko) | 2015-07-01 |
| EP2911663A4 (en) | 2016-04-13 |
| JP2015535252A (ja) | 2015-12-10 |
| WO2014066491A1 (en) | 2014-05-01 |
| US9388179B2 (en) | 2016-07-12 |
| US20150284389A1 (en) | 2015-10-08 |
| CA2891056A1 (en) | 2014-05-01 |
| EP2911663B1 (en) | 2020-03-18 |
| RU2015119640A (ru) | 2016-12-20 |
| EP2911663A1 (en) | 2015-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104869992A (zh) | 具有电压门控性钠通道选择性活性的n-取代的吲唑磺酰胺化合物 | |
| US9624208B2 (en) | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels | |
| EP3204359B1 (en) | Tetrahydroisoquinoline derivatives | |
| TWI687419B (zh) | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 | |
| CN106103416B (zh) | 作为trpm8拮抗剂的氮杂螺衍生物 | |
| WO2021087018A1 (en) | Pyridazinones as parp7 inhibitors | |
| EP3074402B1 (en) | Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels | |
| EP2269993B1 (en) | 2-aminoquinazoline derivative | |
| KR102317335B1 (ko) | ＮＩＫ 억제제로서의 신규 3-(1Ｈ-피라졸-4-일)-1Ｈ-피롤로[2,3-ｃ]피리딘 유도체 | |
| EP3390374B1 (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
| TWI822713B (zh) | 適用於治療或預防與其相關之病症之β－３腎上腺素受體的調節劑 | |
| CN103889419A (zh) | 在电压门控钠离子通道中具有选择性活性的苯并噁唑啉酮化合物 | |
| EP2298731A1 (en) | Amide compound | |
| WO2012030944A2 (en) | Quinoline and isoquinoline compounds and methods of use thereof | |
| KR102569031B1 (ko) | Nr2b nmda 수용체 길항제로서의 피롤로피리미딘 유도체 | |
| CN105085482B (zh) | 取代的哌嗪化合物及其使用方法和用途 | |
| CN104520291A (zh) | 用于调节egfr活性的化合物和组合物 | |
| TW201904942A (zh) | 經取代５-氰基吲哚化合物及其用途 | |
| EP3590941A1 (en) | Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof | |
| EP3487853B1 (en) | Bicyclic proline compounds | |
| CN106414443B (zh) | 吡啶并嘧啶二酮衍生物 | |
| CN108349947A (zh) | 四氢吲唑及其医药用途 | |
| HK40039344B (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | |
| HK40039344A (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150826 |
|
| WD01 | Invention patent application deemed withdrawn after publication |